Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments
Belani, C.P.
Seminars in Oncology 26(3 Suppl 10: 15-18
1999
ISSN/ISBN: 0093-7754 PMID: 10437746 Document Number: 503188
The combination of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) with cisplatin is feasible, has manageable toxicity, and is active in stage IIIB/IV non-small cell lung cancer. The four phase II trials completed to date show response rates ranging from 32% to 48% and median survival durations of 8 to 13 months. Based on these results, regimens combining 75 to 100 mg/m2 docetaxel with 75 to 100 mg/m2 cisplatin are now being assessed in randomized phase III comparisons with platinum-containing combinations. The combination of docetaxel and carboplatin also has promising activity, with response rates of 48% (1 complete response and 12 partial responses) seen in 27 evaluable patients. Overall, this combination is also well tolerated. However, it will be necessary to use both docetaxel/platinum regimens at earlier stages in the disease if a significant impact is to be made on survival.